{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:11:35Z","timestamp":1790946695164,"version":"4.1.0"},"reference-count":98,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,23]],"date-time":"2018-02-23T00:00:00Z","timestamp":1519344000000},"content-version":"vor","delay-in-days":387,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuron"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.neuron.2017.01.018","type":"journal-article","created":{"date-parts":[[2017,2,22]],"date-time":"2017-02-22T18:46:07Z","timestamp":1487789167000},"page":"737-746","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":158,"title":["The Complicated Relationship between Gaucher Disease and Parkinsonism: Insights from a Rare Disease"],"prefix":"10.1016","volume":"93","author":[{"given":"Elma","family":"Aflaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Westbroek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Sidransky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuron.2017.01.018_bib1","doi-asserted-by":"crossref","first-page":"240ra73","DOI":"10.1126\/scitranslmed.3008659","article-title":"Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs","volume":"6","author":"Aflaki","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.neuron.2017.01.018_bib2","doi-asserted-by":"crossref","first-page":"7441","DOI":"10.1523\/JNEUROSCI.0636-16.2016","article-title":"A new Glucocerebrosidase chaperone reduces \u03b1-Synuclein and glycolipid levels in iPSC-derived dopaminergic neurons from patients with Gaucher disease and parkinsonism","volume":"36","author":"Aflaki","year":"2016","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuron.2017.01.018_bib3","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1056\/NEJMoa033277","article-title":"Mutations in the glucocerebrosidase gene and Parkinson\u2019s disease in Ashkenazi Jews","volume":"351","author":"Aharon-Peretz","year":"2004","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.neuron.2017.01.018_bib4","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1001\/archneurol.2010.198","article-title":"Chaperone-mediated autophagy markers in Parkinson disease brains","volume":"67","author":"Alvarez-Erviti","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuron.2017.01.018_bib5","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.1093\/hmg\/ddv297","article-title":"Altered TFEB-mediated lysosomal biogenesis in Gaucher disease iPSC-derived neuronal cells","volume":"24","author":"Awad","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuron.2017.01.018_bib6","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jamaneurol.2014.2950","article-title":"Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort","volume":"72","author":"Beavan","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuron.2017.01.018_bib7","doi-asserted-by":"crossref","first-page":"122","DOI":"10.5414\/NP300901","article-title":"Gaucher cells are not associated with \u03b1-synuclein neuropathology in infants","volume":"35","author":"Berger-Sieczkowski","year":"2016","journal-title":"Clin. Neuropathol."},{"key":"10.1016\/j.neuron.2017.01.018_bib8","series-title":"The Metabolic & Molecular Bases of Inherited Disease","first-page":"3635","article-title":"Gaucher disease","author":"Beutler","year":"2001"},{"issue":"Suppl 1","key":"10.1016\/j.neuron.2017.01.018_bib9","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/jnc.13517","article-title":"Parkinson\u2019s disease: acid-glucocerebrosidase activity and alpha-synuclein clearance","volume":"139","author":"Blanz","year":"2016","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuron.2017.01.018_bib10","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.3390\/biom5042675","article-title":"Alpha-Synuclein as a mediator in the interplay between aging and Parkinson\u2019s disease","volume":"5","author":"Bobela","year":"2015","journal-title":"Biomolecules"},{"key":"10.1016\/j.neuron.2017.01.018_bib11","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.bcmd.2012.11.011","article-title":"Phenotype in patients with Gaucher disease and Parkinson disease","volume":"50","author":"Chetrit","year":"2013","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.neuron.2017.01.018_bib12","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.nbd.2006.08.021","article-title":"Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson\u2019s disease?","volume":"25","author":"Chu","year":"2007","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuron.2017.01.018_bib13","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.nbd.2009.05.023","article-title":"Alterations in lysosomal and proteasomal markers in Parkinson\u2019s disease: relationship to alpha-synuclein inclusions","volume":"35","author":"Chu","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuron.2017.01.018_bib14","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/ana.24777","article-title":"Survival and dementia in GBA-associated Parkinson\u2019s disease: the mutation matters","volume":"80","author":"Cilia","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuron.2017.01.018_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuint.2012.10.010","article-title":"Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage","volume":"62","author":"Cleeter","year":"2013","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuron.2017.01.018_bib16","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1126\/science.1101738","article-title":"Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy","volume":"305","author":"Cuervo","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.neuron.2017.01.018_bib17","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/ana.22400","article-title":"Acid \u03b2-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter \u03b1-synuclein processing","volume":"69","author":"Cullen","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuron.2017.01.018_bib18","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.parkreldis.2015.06.016","article-title":"The contribution of Niemann-Pick SMPD1 mutations to Parkinson disease in Ashkenazi Jews","volume":"21","author":"Dagan","year":"2015","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.neuron.2017.01.018_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000447450","article-title":"LRRK2, GBA and SMPD1 founder mutations and Parkinson\u2019s disease in Ashkenazi Jews","volume":"42","author":"Dagan","year":"2016","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.1016\/j.neuron.2017.01.018_bib20","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/jamaneurol.2016.2245","article-title":"Association of GBA mutations and the E326K polymorphism with motor and cognitive progression in Parkinson disease","volume":"73","author":"Davis","year":"2016","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuron.2017.01.018_bib21","doi-asserted-by":"crossref","first-page":"E1817","DOI":"10.1073\/pnas.1305623110","article-title":"TFEB-mediated autophagy rescues midbrain dopamine neurons from \u03b1-synuclein toxicity","volume":"110","author":"Decressac","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.neuron.2017.01.018_bib22","doi-asserted-by":"crossref","first-page":"e60674","DOI":"10.1371\/journal.pone.0060674","article-title":"Loss of \u03b2-glucocerebrosidase activity does not affect alpha-synuclein levels or lysosomal function in neuronal cells","volume":"8","author":"Dermentzaki","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.neuron.2017.01.018_bib23","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.stemcr.2016.01.013","article-title":"ER stress and autophagic perturbations lead to elevated extracellular \u03b1-Synuclein in GBA-N370S Parkinson\u2019s iPSC-derived dopamine neurons","volume":"6","author":"Fernandes","year":"2016","journal-title":"Stem Cell Reports"},{"key":"10.1016\/j.neuron.2017.01.018_bib24","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1212\/WNL.0000000000001315","article-title":"Differential effects of severe vs mild GBA mutations on Parkinson disease","volume":"84","author":"Gan-Or","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neuron.2017.01.018_bib25","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1172\/JCI58767","article-title":"Identification of embryonic stem cell-derived midbrain dopaminergic neurons for engraftment","volume":"122","author":"Ganat","year":"2012","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.neuron.2017.01.018_bib26","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/ana.23614","article-title":"Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains","volume":"72","author":"Gegg","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuron.2017.01.018_bib27","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/jmg.2004.024455","article-title":"Parkinsonism among Gaucher disease carriers","volume":"41","author":"Goker-Alpan","year":"2004","journal-title":"J.\u00a0Med. Genet."},{"key":"10.1016\/j.neuron.2017.01.018_bib28","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/archneur.65.10.1353","article-title":"The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations","volume":"65","author":"Goker-Alpan","year":"2008","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuron.2017.01.018_bib29","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1093\/brain\/aws174","article-title":"The neurobiology of glucocerebrosidase-associated parkinsonism: a positron emission tomography study of dopamine synthesis and regional cerebral blood flow","volume":"135","author":"Goker-Alpan","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.neuron.2017.01.018_bib30","doi-asserted-by":"crossref","first-page":"e29861","DOI":"10.1371\/journal.pone.0029861","article-title":"High throughput screening for small molecule therapy for Gaucher disease using patient tissue as the source of mutant glucocerebrosidase","volume":"7","author":"Goldin","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.neuron.2017.01.018_bib31","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ymgme.2013.12.005","article-title":"Lysosomal integral membrane protein-2: a new player in lysosome-related pathology","volume":"111","author":"Gonzalez","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.neuron.2017.01.018_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbiotec.2016.01.015","article-title":"A peptide-linked recombinant glucocerebrosidase for targeted neuronal delivery: Design, production, and assessment","volume":"221","author":"Gramlich","year":"2016","journal-title":"J.\u00a0Biotechnol."},{"key":"10.1016\/j.neuron.2017.01.018_bib33","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.bbrc.2015.01.024","article-title":"Dissociation of glucocerebrosidase dimer in solution by its co-factor, saposin C","volume":"457","author":"Gruschus","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuron.2017.01.018_bib34","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10571-015-0309-0","article-title":"Delivery of therapeutic proteins via extracellular vesicles: review and potential treatments for Parkinson\u2019s disease, Glioma, and Schwannoma","volume":"36","author":"Hall","year":"2016","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.neuron.2017.01.018_bib35","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/humu.23056","article-title":"New directions in Gaucher disease","volume":"37","author":"Horowitz","year":"2016","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.neuron.2017.01.018_bib36","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/14789450.2016.1174583","article-title":"Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease","volume":"13","author":"Jung","year":"2016","journal-title":"Expert Rev. Proteomics"},{"key":"10.1016\/j.neuron.2017.01.018_bib37","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/j.1742-4658.2010.07588.x","article-title":"The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase","volume":"277","author":"Khanna","year":"2010","journal-title":"FEBS J."},{"key":"10.1016\/j.neuron.2017.01.018_bib38","doi-asserted-by":"crossref","first-page":"12068","DOI":"10.1073\/pnas.96.21.12068","article-title":"Release of calcium from stores alters the morphology of dendritic spines in cultured hippocampal neurons","volume":"96","author":"Korkotian","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.neuron.2017.01.018_bib39","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/ana.24781","article-title":"Specifically neuropathic Gaucher\u2019s mutations accelerate cognitive decline in Parkinson\u2019s","volume":"80","author":"Liu","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuron.2017.01.018_bib40","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3390\/biom5020435","article-title":"The interplay between Alpha-Synuclein clearance and spreading","volume":"5","author":"Lopes da Fonseca","year":"2015","journal-title":"Biomolecules"},{"key":"10.1016\/j.neuron.2017.01.018_bib41","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1212\/NXG.0000000000000057","article-title":"Clinical course and prognosis in patients with Gaucher disease and parkinsonism","volume":"2","author":"Lopez","year":"2016","journal-title":"Neurol Genet"},{"key":"10.1016\/j.neuron.2017.01.018_bib42","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.braindev.2012.05.008","article-title":"The chaperone activity and toxicity of ambroxol on Gaucher cells and normal mice","volume":"35","author":"Luan","year":"2013","journal-title":"Brain Dev."},{"key":"10.1016\/j.neuron.2017.01.018_bib43","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ymgme.2003.11.004","article-title":"Glucocerebrosidase mutations in subjects with parkinsonism","volume":"81","author":"Lwin","year":"2004","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.neuron.2017.01.018_bib44","doi-asserted-by":"crossref","first-page":"23502","DOI":"10.1074\/jbc.M109.012393","article-title":"Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease","volume":"284","author":"Maegawa","year":"2009","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuron.2017.01.018_bib45","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1212\/NXG.0000000000000104","article-title":"GBA p.T369M substitution in Parkinson disease: polymorphism or association? A meta-analysis","volume":"2","author":"Mallett","year":"2016","journal-title":"Neurol Genet"},{"key":"10.1016\/j.neuron.2017.01.018_bib46","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ymgme.2013.01.012","article-title":"Is Parkinson disease associated with lysosomal integral membrane protein type-2?: challenges in interpreting association data","volume":"108","author":"Maniwang","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.neuron.2017.01.018_bib47","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.neuro.2009.06.009","article-title":"Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism","volume":"30","author":"Manning-Bo\u011f","year":"2009","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.neuron.2017.01.018_bib48","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.parkreldis.2016.10.014","article-title":"SMPD1 variants in Chinese Han patients with sporadic Parkinson\u2019s disease","volume":"34","author":"Mao","year":"2016","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.neuron.2017.01.018_bib49","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1750-1172-8-140","article-title":"Unfolded protein response in Gaucher disease: from human to Drosophila","volume":"8","author":"Maor","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.neuron.2017.01.018_bib50","first-page":"2712","article-title":"The contribution of mutant GBA to the development of Parkinson disease in Drosophila","volume":"25","author":"Maor","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuron.2017.01.018_bib51","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1002\/jnr.23751","article-title":"Beyond Krabbe\u2019s disease: the potential contribution of galactosylceramidase deficiency to neuronal vulnerability in late-onset synucleinopathies","volume":"94","author":"Marshall","year":"2016","journal-title":"J.\u00a0Neurosci. Res."},{"key":"10.1016\/j.neuron.2017.01.018_bib52","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/mt.2016.53","article-title":"CNS-accessible inhibitor of glucosylceramide synthase for substrate reduction therapy of neuronopathic Gaucher disease","volume":"24","author":"Marshall","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neuron.2017.01.018_bib53","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/mds.26359","article-title":"GBA variants are associated with a distinct pattern of cognitive deficits in Parkinson\u2019s disease","volume":"31","author":"Mata","year":"2016","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuron.2017.01.018_bib54","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","article-title":"Gaucher disease glucocerebrosidase and \u03b1-synuclein form a bidirectional pathogenic loop in synucleinopathies","volume":"146","author":"Mazzulli","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.neuron.2017.01.018_bib55","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1073\/pnas.1520335113","article-title":"\u03b1-Synuclein-induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models","volume":"113","author":"Mazzulli","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.neuron.2017.01.018_bib56","doi-asserted-by":"crossref","first-page":"7693","DOI":"10.1523\/JNEUROSCI.0628-16.2016","article-title":"Activation of \u03b2-Glucocerebrosidase reduces pathological \u03b1-Synuclein and restores lysosomal function in Parkinson\u2019s patient midbrain neurons","volume":"36","author":"Mazzulli","year":"2016","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuron.2017.01.018_bib57","doi-asserted-by":"crossref","first-page":"9322","DOI":"10.1073\/pnas.1500937112","article-title":"Cysteine cathepsins are essential in lysosomal degradation of \u03b1-synuclein","volume":"112","author":"McGlinchey","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.neuron.2017.01.018_bib58","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/brain\/awu020","article-title":"Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells","volume":"137","author":"McNeill","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.neuron.2017.01.018_bib59","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/mds.24886","article-title":"Evidence of an association between the scavenger receptor class B member 2 gene and Parkinson\u2019s disease","volume":"27","author":"Michelakakis","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuron.2017.01.018_bib60","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/brain\/awt367","article-title":"Reduced glucocerebrosidase is associated with increased \u03b1-synuclein in sporadic Parkinson\u2019s disease","volume":"137","author":"Murphy","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.neuron.2017.01.018_bib61","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1001\/jamaneurol.2013.1925","article-title":"A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies","volume":"70","author":"Nalls","year":"2013","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuron.2017.01.018_bib62","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/acn3.292","article-title":"Ambroxol chaperone therapy for neuronopathic Gaucher disease: A pilot study","volume":"3","author":"Narita","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.neuron.2017.01.018_bib63","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/qjmed\/89.9.691","article-title":"Occurrence of Parkinson\u2019s syndrome in type I Gaucher disease","volume":"89","author":"Neudorfer","year":"1996","journal-title":"QJM"},{"key":"10.1016\/j.neuron.2017.01.018_bib64","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.1021\/jm300063b","article-title":"Discovery, structure-activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidase","volume":"55","author":"Patnaik","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuron.2017.01.018_bib65","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.nbd.2004.09.004","article-title":"Enhanced calcium release in the acute neuronopathic form of Gaucher disease","volume":"18","author":"Pelled","year":"2005","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuron.2017.01.018_bib66","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.bbamem.2011.07.032","article-title":"Biophysics of \u03b1-synuclein membrane interactions","volume":"1818","author":"Pfefferkorn","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.neuron.2017.01.018_bib67","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the alpha-synuclein gene identified in families with Parkinson\u2019s disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.neuron.2017.01.018_bib68","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3390\/biom5020282","article-title":"Seeking a mechanism for the toxicity of oligomeric \u03b1-synuclein","volume":"5","author":"Roberts","year":"2015","journal-title":"Biomolecules"},{"key":"10.1016\/j.neuron.2017.01.018_bib69","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/acn3.177","article-title":"Progressive decline of glucocerebrosidase in aging and Parkinson\u2019s disease","volume":"2","author":"Rocha","year":"2015","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.neuron.2017.01.018_bib70","first-page":"2645","article-title":"Glucocerebrosidase modulates cognitive and motor activities in murine models of Parkinson\u2019s disease","volume":"25","author":"Rockenstein","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuron.2017.01.018_bib71","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.bcmd.2010.10.006","article-title":"The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher Registry","volume":"46","author":"Rosenbloom","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.neuron.2017.01.018_bib72","doi-asserted-by":"crossref","first-page":"15573","DOI":"10.1073\/pnas.1405700111","article-title":"LIMP-2 expression is critical for \u03b2-glucocerebrosidase activity and \u03b1-synuclein clearance","volume":"111","author":"Rothaug","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.neuron.2017.01.018_bib73","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1073\/pnas.1220464110","article-title":"Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies","volume":"110","author":"Sardi","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.neuron.2017.01.018_bib74","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.pneurobio.2014.12.001","article-title":"Gaucher-related synucleinopathies: the examination of sporadic neurodegeneration from a rare (disease) angle","volume":"125","author":"Sardi","year":"2015","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuron.2017.01.018_bib75","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1126\/science.1174447","article-title":"A gene network regulating lysosomal biogenesis and function","volume":"325","author":"Sardiello","year":"2009","journal-title":"Science"},{"issue":"Pt A","key":"10.1016\/j.neuron.2017.01.018_bib76","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.mcn.2015.03.013","article-title":"Glucocerebrosidase and Parkinson disease: recent advances","volume":"66","author":"Schapira","year":"2015","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.neuron.2017.01.018_bib77","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1038\/ncomms5028","article-title":"iPSC-derived neurons from GBA1-associated Parkinson\u2019s disease patients show autophagic defects and impaired calcium homeostasis","volume":"5","author":"Sch\u00f6ndorf","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuron.2017.01.018_bib78","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.4161\/auto.7.11.17166","article-title":"TFEB regulates autophagy: an integrated coordination of cellular degradation and recycling processes","volume":"7","author":"Settembre","year":"2011","journal-title":"Autophagy"},{"key":"10.1016\/j.neuron.2017.01.018_bib79","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/emboj.2012.32","article-title":"A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB","volume":"31","author":"Settembre","year":"2012","journal-title":"EMBO J."},{"key":"10.1016\/j.neuron.2017.01.018_bib80","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/ncb2718","article-title":"TFEB controls cellular lipid metabolism through a starvation-induced autoregulatory loop","volume":"15","author":"Settembre","year":"2013","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.neuron.2017.01.018_bib81","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1002\/mds.23774","article-title":"Lysosomal storage disorders and Parkinson\u2019s disease: Gaucher disease and beyond","volume":"26","author":"Shachar","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuron.2017.01.018_bib82","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","article-title":"Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease","volume":"361","author":"Sidransky","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.neuron.2017.01.018_bib83","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1093\/brain\/awu002","article-title":"Glucocerebrosidase is shaking up the synucleinopathies","volume":"137","author":"Siebert","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.neuron.2017.01.018_bib84","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.neuron.2016.05.040","article-title":"The evolution of genetics: Alzheimer\u2019s and Parkinson\u2019s diseases","volume":"90","author":"Singleton","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.neuron.2017.01.018_bib85","doi-asserted-by":"crossref","first-page":"292","DOI":"10.5607\/en.2014.23.4.292","article-title":"Alpha-synuclein function and dysfunction on cellular membranes","volume":"23","author":"Snead","year":"2014","journal-title":"Exp. Neurobiol."},{"key":"10.1016\/j.neuron.2017.01.018_bib86","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.neuron.2017.01.018_bib87","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1074\/jbc.M111.280016","article-title":"Ex\u00a0vivo and in\u00a0vivo effects of isofagomine on acid \u03b2-glucosidase variants and substrate levels in Gaucher disease","volume":"287","author":"Sun","year":"2012","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuron.2017.01.018_bib88","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1006\/mgme.2001.3201","article-title":"Gaucher disease and parkinsonism: a phenotypic and genotypic characterization","volume":"73","author":"Tayebi","year":"2001","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.neuron.2017.01.018_bib89","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1310\/hpj5107-553","article-title":"Enzyme replacement or substrate reduction? A review of Gaucher disease treatment options","volume":"51","author":"Van Rossum","year":"2016","journal-title":"Hosp. Pharm."},{"key":"10.1016\/j.neuron.2017.01.018_bib90","doi-asserted-by":"crossref","first-page":"35863","DOI":"10.1074\/jbc.M111.253450","article-title":"Effect of Ser-129 phosphorylation on interaction of \u03b1-synuclein with synaptic and cellular membranes","volume":"286","author":"Visanji","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuron.2017.01.018_bib91","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ymgme.2014.11.008","article-title":"The clinical management of Type 2 Gaucher disease","volume":"114","author":"Weiss","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.neuron.2017.01.018_bib92","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1002\/mds.26802","article-title":"Lysosomal trafficking defects link Parkinson\u2019s disease with Gaucher\u2019s disease","volume":"31","author":"Wong","year":"2016","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuron.2017.01.018_bib93","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.celrep.2014.10.023","article-title":"iPSC-derived dopamine neurons reveal differences between monozygotic twins discordant for Parkinson\u2019s disease","volume":"9","author":"Woodard","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.neuron.2017.01.018_bib94","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.3390\/biom5031634","article-title":"Toxic oligomeric Alpha-Synuclein variants present in human Parkinson\u2019s disease brains are differentially generated in mammalian cell models","volume":"5","author":"Xin","year":"2015","journal-title":"Biomolecules"},{"key":"10.1016\/j.neuron.2017.01.018_bib95","doi-asserted-by":"crossref","first-page":"28080","DOI":"10.1074\/jbc.M111.237859","article-title":"Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases","volume":"286","author":"Yap","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuron.2017.01.018_bib96","doi-asserted-by":"crossref","first-page":"7161","DOI":"10.1021\/bi401191v","article-title":"Saposin C protects glucocerebrosidase against \u03b1-synuclein inhibition","volume":"52","author":"Yap","year":"2013","journal-title":"Biochemistry"},{"key":"10.1016\/j.neuron.2017.01.018_bib97","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1074\/jbc.M114.610584","article-title":"Structural features of membrane-bound glucocerebrosidase and \u03b1-synuclein probed by neutron reflectometry and fluorescence spectroscopy","volume":"290","author":"Yap","year":"2015","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuron.2017.01.018_bib98","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.bcmd.2012.09.006","article-title":"Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease","volume":"50","author":"Zimran","year":"2013","journal-title":"Blood Cells Mol. Dis."}],"container-title":["Neuron"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896627317300429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896627317300429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,27]],"date-time":"2019-04-27T12:52:03Z","timestamp":1556369523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896627317300429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":98,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S0896627317300429"],"URL":"https:\/\/doi.org\/10.1016\/j.neuron.2017.01.018","relation":{},"ISSN":["0896-6273"],"issn-type":[{"value":"0896-6273","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Complicated Relationship between Gaucher Disease and Parkinsonism: Insights from a Rare Disease","name":"articletitle","label":"Article Title"},{"value":"Neuron","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuron.2017.01.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}